Serina Therapeutics Reports $7.9M Q3 Net Loss; SER-252 Advances to Cohort 2

Serina Therapeutics reported third-quarter 2026 revenue of $125,000 and a net loss attributable to common stockholders of $7.9 million, or $0.31 per share. Cash and cash equivalents totaled $19.4 million at September 30, 2026. The company also began dosing Cohort 2 in its SER-252 study for advanced…